In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.
In this webinar, Prof. Ed Schuuring of University Medical Center Groningen reports on a comparison study for the detection of mutations in plasma DNA of NSCLC patients using the Roche Cobas EGFR v2.0 Mutation Test, BioRad droplet digital PCR, and the Agena Bioscience UltraSEEK Lung Panel. Prof. Schuuring discusses the detection sensitivity of clinically relevant markers across the platforms and also highlights the relevance of pre-analytical quality and quantity assessment of cfDNA.
Dr. Alexander Sartori from Agena Bioscience follows with an overview of the MALDI-TOF based MassARRAY System and available mutation panels for both tissue and plasma DNA in various cancers.
Learn more about our liquid biopsy solutions.
